ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0458

Acinetobacter Bacteremia in Patients with ESKD and Tunneled Dialysis Catheters

Session Information

  • Dialysis: Vascular Access
    November 08, 2025 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 803 Dialysis: Vascular Access

Authors

  • Zaman, Jesan, Emory University School of Medicine, Atlanta, Georgia, United States
  • Owosela, Babajide O, Emory University School of Medicine, Atlanta, Georgia, United States
  • Gammada, Leilani E., Tulane University School of Medicine, New Orleans, Louisiana, United States
  • Niyyar, Vandana Dua, Emory University School of Medicine, Atlanta, Georgia, United States
  • Cobb, Jason, Emory University School of Medicine, Atlanta, Georgia, United States
Background

Sepsis is the second leading cause of death in ESKD patients. Catheter-related bloodstream infections are a significant source of morbidity and mortality. There is a paucity of data of Acinetobacter infections in the ESKD patient population which have been limited to a few case reports mostly in peritoneal dialysis. We present the largest case series of Acinetobacter bacteremia in ESKD hemodialysis patients using a tunneled dialysis catheter for hemodialysis access.

Methods

Reviewed records of Acinetobacter bacteremia in patients at Emory University Hospital Midtown and Emory Dialysis (academic outpatient HD centers) from 2010 – 2024. Patients with arteriovenous fistula (AVF) or arteriovenous graft (AVG) as primary HD vascular access were excluded.

Results

10 cases with Acinetobacter bacteremia, 8 cases included (all Acinetobacter baumannii and pan-sensitive), and 2 excluded due to AVG or AVF primary HD access. Average HD vintage: 2.98 years. Tunneled HD catheter access – internal jugular (n=7) and left femoral (n=1). Common comorbidities included hypertension (n = 6), diabetes mellitus (n=4), and HIV (n=4). At the time of presentation: febrile (n = 3), mean peak WBC 8.2 x 103/µL with only 1 patient >10 x 103/µL. Patients treated with antibiotics for 2-6 weeks. All 8 patients had tunneled HD catheter removed. Three patients with guidewire catheter exchange, 2 with HD catheter removed and line holiday (1 for 2 days and other for 5 days) before tunneled HD catheter replaced, and 3 patients had maturing AVG/AVF with tunneled HD catheter removed and transitioned to the AVG/AVF. No reported documentation of recurrent Acinetobacter bacteremia (n=6).

Conclusion

Acinetobacter bacteremia is associated with hospital-acquired infections & no patient had recent hospitalization, but we argue that outpatient HD centers are possible risk factors. Three of the 8 patients had pre-existing maturing AVG or AVF and were able to successfully transition to use of the AVG/AVF, and quick removal of tunneled dialysis catheters could have prevented 3 of the cases. Of note, 50% of the patients had HIV and guidewire catheter exchange (n=3) was a successful treatment therapy. This case series provides useful information about demographics and outcomes in ESKD patients with Acinetobacter bacteremia attributed to tunneled dialysis access.

Digital Object Identifier (DOI)